Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC

Prior treatment

• Requirement for systemic glucocorticoid therapy or other immunosuppressive treatments;
• Probiotic use within 3 months prior to enrollment;
• Presence of bronchiectasis, concurrent pulmonary infections, pulmonary fibrosis, or uncontrolled diabetes mellitus;
• Receipt of chemotherapy or any other cancer treatment prior to enrollment;
• Previous treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies.

Other illness

• Use of antibiotics or presence of infections requiring antibiotic therapy within the past 3 months;
• Presence of obstructive pneumonia, cancerous cavitation, or active pulmonary tuberculosis;
• Active or pre-existing autoimmune diseases;
• Uncontrolled comorbidities including heart failure, uncontrolled hypertension, unstable angina, or interstitial lung disease;
• Positive for hepatitis B surface antigen or detectable hepatitis C RNA requiring treatment;
• Known history or positive test for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS);

Other

• Presence of a primary tumor in another organ;
• Confirmed brain metastases by contrast-enhanced MRI before enrollment;
• Pregnant or breastfeeding women;

• Age between 18 and 80 years;
• Newly diagnosed, driver gene-negative non-small cell lung cancer (NSCLC) confirmed by histopathology (Stage IIA-IIIB);
• At least one measurable lesion as defined by RECIST version 1.1; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
• No prior systemic therapy or radiotherapy;
• Eligible for surgical resection and suitable for neoadjuvant immunotherapy or chemotherapy as determined by multidisciplinary evaluation;
• Signed written informed consent prior to study participation;
• Adequate pulmonary ventilation and diffusion function confirmed by pre-enrollment pulmonary function test to allow for surgical resection.